As of November 6, 2026, Arcturus Therapeutics Holdings Inc. is a publicly traded company (Nasdaq: ARCT); its largest reported holder is ARK Invest, with 10.37% on Schedule 13G/A of May 7, 2026, then Amova Asset Management Americas, Inc. (7.2%) (Schedule 13G/A, May 7, 2026).
Is this your company?
About to sign with, pay or invest in Arcturus Therapeutics Holdings Inc.? See the free Snapshot first.
Free to see. No signup.
Is Arcturus Therapeutics Holdings Inc. a real, registered company?
- Arcturus Therapeutics Holdings Inc. files with the SEC under CIK 1768224 (its SEC filings).
- Its shares are listed under the ticker ARCT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Arcturus Therapeutics Holdings Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Dennis Mulroy, Chief Financial Officer (Form 8-K filed 2026-05-07). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Sumitomo Mitsui Trust Group, Inc. (filed 2026-10-29).
Who are Arcturus Therapeutics Holdings Inc.'s owners and officers?
Arcturus Therapeutics Holdings Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-29).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-29 | Sumitomo Mitsui Trust Group, Inc. | 5.9% |
| Schedule 13G/A, 2026-10-07 | Federated Hermes, Inc. | 5.9% |
| Schedule 13G/A, 2026-05-07 | Ark Investment Management LLC | 10.37% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Balyasny Asset Management L.P. | 0% |
| Schedule 13G/A, 2026-02-03 | Ark Investment Management LLC | 9.19% |
| Schedule 13G/A, 2026-01-08 | Federated Hermes, Inc. | 11.63% |
| Schedule 13G, 2025-11-14 | Balyasny Asset Management L.P. | 8.04% |
| Schedule 13G/A, 2025-11-13 | Amova Asset Management Americas, Inc. | 7.2% |
| Schedule 13G/A, 2025-10-27 | Sumitomo Mitsui Trust Group, Inc. | 7.2% |
| Schedule 13G/A, 2025-07-30 | Ark Investment Management LLC | 6.32% |
| Schedule 13G/A, 2025-07-29 | The Vanguard Group | 6.67% |
Questions about who owns Arcturus Therapeutics Holdings Inc.
Who owns Arcturus Therapeutics Holdings Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Arcturus Therapeutics Holdings Inc.: Ark Investment Management LLC (10.37%, Schedule 13G/A, filed 2026-05-07), Amova Asset Management Americas, Inc. (7.2%, Schedule 13G/A, filed 2025-11-13), Sumitomo Mitsui Trust Group, Inc. (5.9%, Schedule 13G/A, filed 2026-10-29) and Federated Hermes, Inc. (5.9%, Schedule 13G/A, filed 2026-10-07).
Who are the largest shareholders of Arcturus Therapeutics Holdings Inc.?
By the share each holder's latest filing reports, the largest holders of Arcturus Therapeutics Holdings Inc. on this page are Ark Investment Management LLC (10.37%), Amova Asset Management Americas, Inc. (7.2%) and Sumitomo Mitsui Trust Group, Inc. (5.9%).
When did Ark Investment Management LLC buy into Arcturus Therapeutics Holdings Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ark Investment Management LLC on this page is the Schedule 13G/A, filed 2025-07-30, reporting 6.32%; its latest, Schedule 13G/A filed 2026-05-07, reports 10.37%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Arcturus Therapeutics Holdings Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Arcturus Therapeutics Holdings Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arcturus Therapeutics Holdings Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-05-07 | Dennis Mulroy | Chief Financial Officer | appointed | 2026-05-01 |
| Form 8-K, 2026-05-07 | Dennis Mulroy | appointed |
Which insiders own Arcturus Therapeutics Holdings Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief operating officer and chief scientific officer: 435,334 shares (1.5% of shares outstanding) (Form 4, 2024-10-16).
- , the chief financial officer and a director: 221,764 shares (0.77% of shares outstanding) (Form 4/A, 2025-08-20).
- , the controller: 2,201 shares (0.01% of shares outstanding), 2,001 held directly and 200 indirectly (Form 3, 2025-12-19).
Shares outstanding: 28,822,514 as of 2026-11-03, from the company's latest SEC cover page.
How much has Arcturus Therapeutics Holdings Inc. raised?
No fundraising or offering filing from Arcturus Therapeutics Holdings Inc. is on file with us.
Keep reading
More on Arcturus Therapeutics Holdings Inc. and the records around it.
Arcturus Therapeutics Holdings Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes May 2026
Companies that share a holder
- Amova Asset Management Americas, Inc. also filed stake reports on 3 other companies: Ibotta, Inc. (Feb 2026), 10x Genomics, Inc. (Nov 2025)
- Sumitomo Mitsui Trust Group, Inc. also filed stake reports on 7 other companies: GCM Grosvenor Inc. (Apr 2026), Ibotta, Inc. (Feb 2026), 10x Genomics, Inc. (Oct 2025)
- Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Forte Biosciences, Inc. (Sep 2026), SCYNEXIS INC (Jul 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/arcturus-therapeutics